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S300 Poster Session Ifrom 2000-2011. Patients included in the analysis all achieved CR1
or PR1 by CIBMTR definition prior to transplant. Patients who re-
ceived tandem transplants, allogeneic transplants, or whowere trans-
planted on clinical protocol were excluded. Disease status prior to
transplant and disease status 100 days after transplant was recorded
for both patients younger than 65 and 65 years of age and older.
Data from transplants of 117 patients were analyzed. 32 patients
(27%) were age 65 and older, and 85 patients (73%) were younger
than age 65. Prior to transplant, 20/32 patients (63%) age 65 and
above were in CR or VGPR compared to 23/85 (27%) of patients
younger than age 65. At 100-day restaging after transplant, 25/32 pa-
tients (78%) age 65 and above achieved a CR or VGPR compared to
44/85 patients (52%) younger than 65. There was one transplant-re-
lated death in each age group corresponding to a transplant-related
mortality of 3% and 1% in the older and younger age groups, respec-
tively. Two patients who were both younger than age 65 had evi-
dence of progressive disease at 100-day restaging.
Based on our single-institution analysis, multiple myeloma pa-
tients age 65 and above have experienced similar outcomes compared
to younger patients with respect to transplant-related mortality and
disease status 100-days after transplant. Specifically both age groups
experienced a consolidative benefit to high-dose therapy followed by
autologous SCT. Prospective studies evaluating the impact of age on
transplant outcome should be performed for further investigation.
Table 1. Characteristics of Myeloma Patients Transplanted at
Temple from 2000-2011Number of PatientsTable 1.
Patient # AGE
Induction pre
1st Transplant
1 46 VAD X4 then
Thalidomide
for 1 year
C
2 66 VAD X4 C
3 56 Thal/Dex then
Bro/Dex then MP
C
4 67 Lenalidomide/Dex  4 G
X indicates number of cycles; RVD, lenalidomide
Doxorubicin, Cytoxan, Etoposide; Bro, Brotezom117
Median Age 58
Range of Ages 40-77
Age 65 and greater 32
Younger than Age 65 85
Number of Males 70
Number of Females 47
IgG Subtype 62
IgA Subtype 24
Free Kappa Light Chain 16
Free Lambda Light Chain 11
Other (IgD, Oligoclonal, Non-secretory) 4
Median Time from diagnosis to BMT 11.5 months
Median CD34 dose 5.56E + 06 cell dose/kg259
SUCCESSFUL STEM CELL MOBILIZATION AND ENGRAFTMENT IN
HEAVILY PRETREATED MULTIPLE MYELOMA PATIENTS WITH PRIOR
HIGH DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTA-
TION
Khaled, Y., Solh, M., Lamontagne, D., Batista, A., Sullivan, J., Chan-
Fong, S., Fondaw, M., Reddy, V. Florida Cancer Institute, Orlando, FL
Salvage second autologous transplantation for patients with re-
lapsed multiple myeloma (MM) after prior autologous transplanta-
tion has shown to be beneficial in particular if the first remission isMobilization
Regimen
First
Transplant T
ytoxan/G-CSF Single
ytoxan/G-CSF Planned
Tandem
ytoxan/G-CSF Single
-CSF Single
, Bortezomib, Dex.; Thal, Th
ib.longer than 12-18 months. In addition second salvage autologous
transplant may be used in the contest of progressive refractory mye-
loma for temporarily disease control or for hematopoietic reconsti-
tution after prior extensive therapy. Customarily, patients with
multiple myeloma who received prior alkylating agents or autolo-
gous transplantation with high dose Melphalan are considered non
transplant candidate because of the deleterious effects on stem cell
collection. Plerixafor is a chemokine receptor -4- antagonist which
is approved by FDA for use in combination with G-CSF for mobili-
zation of CD34+ stem cells in patients with NHL and multiple my-
eloma. We have explored the feasibility of Plerixafor and G-CSF in
stem cell collection for second salvage autologous transplantation in
4 consecutive patients with multiple myeloma who underwent prior
extensive therapy including prior autologous transplantation with
Melphalan-200. Patient characteristics, chemotherapy used and in-
terval between first and second salvage transplant are shown in
Table 1. All Patients received GCSF at dose of 10 mcg/KG for 4
days in AM, Plerixafor on the evening of the 4th night and subsequent
nights prior to apheresis at a dose of 0.24 mg/kg. The number of
apheresis procedures were 2 in two patients and 3 in two patients.
The number of CD34 + cells collected were 4.25, 3.06, 3.63, 3.78
million cells/Kg. All the patients engrafted successfully after the sec-
ond transplant. Neutrophils engraftement were at day 10, 12, 12 and
11 while platelet engraftment were at day 10, 15, 32 and 19 respec-
tivlely for the four patients.
Our Data shows the feasibility of stem cell collection in heavily
pretreated MM patients including high dose Melphalan and autolo-
gous stem cell transplantation. Prospective studies are needed to
confirm such feasibility. Such approach may have future clinical ap-
plication in eliminating minimal residual disease after the first autol-
ogous transplant when used in MM patients with planned upfront
tandem autologous transplant.
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A TREOSULPHAN BASED REDUCED TOXICITY CONDITIONING PROTO-
COL FOR THALASSAEMIA MAJOR
Raj, R., Munirathnam, D., Khandelwal, V., Sri, K., Bhushan, V.,
Kumar, M., Lakshmanan, V. Apollo Speciality Hospital, Chennai, Tamil-
nadu, India
We present data comparing two conditioning protocols for beta
thalassaemia major in patients treated in our unit from 2005 to
2011.Twenty children aged between 2 and 9 years were treated using
oral busulphan 16 mg/kg/day with cyclophosphamide 200 mg/kg/
day were assigned to group one. Twenty children aged between 1
and 14 years were treated using thiotepa 8 mg/kg, treosulphan 42
gm/m2 and fludarabine 160 mg/m2 were assigned to group two.
Datawas analysed retrospectively forLucarelli class,mucositis, blood
product requirement, need for parenteral nutrition, engraftment and
transplant relatedmortality. Group one had 4 class I, 10 class II and 6
class III patients between age groups 1 to 14 years. Mucositis was
grade two and above in 11 children and they needed partial parenteralype
Maintenance/Relapse
treatment Re-Induction
Interval between
transplants (Years)
Thalidomid then
Lenalidomide
maintenance
RVD  3 8.57
Dex/Thal followed
by Bro/Doxil
MPV-Rituximab 4.77
Dex/Thal then
RVD3 then
VD-PACE
MPV-Rituximab 2 4.43
Lenalidomide
maintennace for
15 months
RVD  4,
VD-PACE 2
1.75
alidomide; MPV, Melphalan, Prednisone , Bortezomib; PACE, Cisplatin,
Poster Session I S301nutrition. Red cell requirement was\ 4 units in 9 children and . 4
units in 11 children. Platelet support was required\5 in 5 children
and. 5 in 15 children. Two of the eighteen children did not engraft
and 4 children had graft versus host disease and 1 child died on day 10
due to acute cardiomyopathy. Two children had mild sinusoidal ob-
struction syndrome. Group two had 9 class I, 3 class II and 8 class III
patients between age groups 1 to 13 years. Mucositis was grade two
and above in 5 children and they needed partial parenteral nutrition.
Less than 4 units of red cells were required in 15 children and . 4
units in 5 children. Platelet support was required on less than occa-
sions in 10 children and . 5 in 10 children. All of the eighteen chil-
dren engrafted and 2 children had graft versus host disease. There
was no mortality and two children had early graft rejection before
day 100. No child had sinusoidal obstruction syndrome.
We conclude that this treosulphan based regimen is well tolerated
and results in durable engraftment even in Class III thalassaemia ma-
jor children with no major toxicity or mortality.
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PULMONARY ARTERYOPATHY AND PULMONARY HYPERTENSION FOL-
LOWING TANDEMAUTOLOGOUS TRANSPLANTS IN PEDIATRIC PATIENTS
WITH CNS TUMORS
Schechter, T.1, Leucht, S.1, Bouffet, E.1, Cutz, E.2,Gassas, A.1,Huang,A.1,
Bartels, U.1, Humpl, T.3, Doyle, J.1 1The Hospital for Sick Children,
Toronto, ON, Canada; 2The Hospital for Sick Children, Toronto, ON,
Canada; 3The Hospital for Sick Children, Toronto, ON, Canada
Introduction: Young children with central nervous system (CNS)
tumors are frequently being treated with tandem cycles of high
dose chemotherapy followed by autologous stem-cell transplants in
an attempt to avoid cranial irradiation. The most common combina-
tions of chemotherapy used is carboplatinum and thiotepa. Though,
multiple side effects were documented, pulmonary arteriopathy
leading to pulmonary hypertension (PH) was not previously docu-
mented in patients treated for primary CNS disease. We herein re-
port PH as a complication post autologous transplantation using
carboplatinum and thiotepa as conditioning therapy.
Methods: A retrospective evaluation of all pediatric patients diag-
nosed with primary CNS tumors between 2001-2010 who were
scheduled to be treated with 3 cycles of high dose chemotherapy
with carboplatinum (17mg/kd/day for 2 days) and thiotepa (10mg/
kg/day for 2 days) followed by autologous stem-cell transplants
was conducted. The primary objective was to evaluate the incidence
of PH in this population and patients’ outcome following the devel-
opment of PH.
Results: 14 patients were scheduled to received 3 cycles of autolo-
gous transplantation. The median age was 28 months (range
3-41months). Patients’ diagnoses were: atypical teratoid rhabdoid
tumor – 8 patients, medulloblastoma- 4 patients and primitive neu-
roectodermal tumor- 2 patients. Three patients developed biopsy
confirmed pulmonary arteriopathy. The two patients that developed
echocardiographic evidence of PH after the third cycle of high dose
therapy succumbed to right heart failure, while one patient who’s PH
was detected after the second cycle didn’t receive the third cycle and
survived this complication. The overall survival (OS) of the 14 pa-
tients was 0.48 +/- 0.15 at a median of 14.32 months (range 4.99-
68.21 months). Death from progression was 0.43 +/- 0.16 and
non-relapsed mortality was 0.15 +/- 0.10. The 2 patients who died
from PH represented the only non-relapsed mortality in our cohort.
Conclusions: Pulmonary hypertension is a major complication fol-
lowing high dose chemotherapy and autologous transplantation with
a high likelihood of mortality despite PH directed therapy. Echocar-
diographic evaluation of the right ventricle and screening specifically
for PH should be included after each cycle of high dose chemother-
apy in pediatric CNS tumor population. Consideration for longer
interval between cycles should be done to allow proper follow-up be-
tween cycles.
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OUTCOMES OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
INHERITED METABOLIC DISORDERS: A REPORT FROM ANZCHOG AND
ABMTRR
Mitchell, R.1, Smith, Nivison-I.2, Teidemann, K.3, Mechinaud, F.3,
Shaw, P.J.4, Teague, L.5, Fraser, C.6, Tapp, H.7, Cole, C.H.8,Alvaro, F.9, O’Brien, T.A.1 1Sydney Children’s Hospital, Sydney, Aus-
tralia; 2Australasian Bone Marrow Transplant Recipient Registry, Syd-
ney, Australia; 3Royal Children’s Hospital, Melbourne, Australia;
4Children’s Hospital Westmead, Sydney, Australia; 5Starship Children’s
Hospital, Auckland, New Zealand; 6Royal Children’s Hospital, Brisbane,
Australia; 7Women and Children’s Hospital, Adelaide, Australia; 8Prin-
cess Margaret Hospital for Children, Perth, Australia; 9John Hunter
Children’s Hospital, Newcastle, Australia
We report a retrospective analysis of 53 haematopoietic stem cell
transplants for inherited metabolic disorders performed at Australia
and New Zealand Children’s Haematology Oncology Group
(ANZCHOG) transplant centres between 1992 and 2008. The
most common indications for transplant were Hurler syndrome
(47%), adrenoleukodystrophy (ALD) (28%) and metachromatic
leukodystrophy (17%). The median age of patients was 2 years
(0-15). 11 (32%) patients received marrow from matched siblings,
1 from an HLA-identical parent. The remaining 66% received
grafts from unrelated donors, with 22 (42%) using single UCB,
13 BM or PBSC (23%) and one double UCB transplant. 55% of pa-
tients received Busulphan and Cyclophosphamide as their condi-
tioning regimen, and 34% received Bu/Cy + Other (Melphalan or
Fludarabine). 54% had in-vivo T cell depletion using ATG or
Campath, and 15% had ex-vivo T cell depletion. Median time to
neutrophil and platelet engraftment was 16 and 35 days respec-
tively, with a cumulative incidence (CI) at day +42 of 94% and
73% respectively. There were 3 graft failures, all engrafted after
a second URD, and are alive at 10, 5 and 3 years post transplant.
The CI of aGVHD grade II-IV and III-IV at day +100 was 39%
and 14% respectively. 17% of patients had cGVHD at 1 year
post transplant. Transplant related mortality (TRM) was 12% at
day +100, and 19% at 1 year post transplant. Overall 5 year survival
(OS) was 78% for the cohort, with 73% for ALD and 83% for
Hurler syndrome. There were no late deaths reported for the co-
hort, with median follow up of 4 years. Neither age, year of trans-
plant, donor source, or HLA match impacted OS. In contrast, the
development of interstitial pneumonitis was the only significant var-
iable associated with an increase in TRM and decrease in OS. This
is keeping with previously reported literature for this patient co-
hort1. In summary, we report excellent OS in a large cohort of pa-
tients transplanted for a range of metabolic disorders.
1. Orchard PJ,Milla C, Braulin E et al. ‘‘Pre-transplant risk factors
affecting outcome in Hurler syndrome’’ Bone marrow transplant.
(2010) 45: 1239-1246.263
CHEMOTHERAPY-ONLY PREPARATIVE REGIMEN FOR ALTERNATIVE DO-
NOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS
WITH FANCONI ANEMIA
Mehta, P.A.1, Davies, S.M.1, Duncan, C.2, Guinan, E.2, Klein, E.4,
Edwards, S.1, Lehmann, L.2, Margolis, D.3, Williams, D.2, Boulad, F.4
1Cincinnati Children’s Hospital Medical Center, OH; 2Boston Children’s
Hospital, MA; 3Children’s Hospital of Wisconsin, WI; 4Memorial Sloan-
Kettering Hospital, NY
Background: A significant number of patients with Fanconi anemia
(FA) who survive hematopoietic stem cell transplantation (HSCT),
develop solid tumors. The relative contributions of total body irradi-
ation (TBI) and chronic graft vs. host disease (GvHD) to the devel-
opment of tumors are unknown. Our study aims to examine whether
non-TBI based preparative regimen improves alternative donor
HSCToutcome in FA.Here we report results of our interim analysis
after first 17 patients.
Methods: Seventeen patients were enrolled in this phase II multi-
center protocol between June 2009 and October 2011. See Table 1
for patient and donor characteristics. Preparative regimen in-
cluded: Busulfan 0.8-1.0 mg/Kg/dose Q 12H x 4 doses (D-7&-6),
Cyclophosphamide 10 mg/Kg/day, Fludarabine 35 mg/m2/day and
Rabbit ATG 2.5 mg/Kg/day x 4 days (D-5 to D-2).GvHD pro-
phylaxis was cyclosporine starting D-2. Filgrastim was used starting
D+1. Busulfan doses were adjusted to keep the steady state con-
centration low in most cases. All grafts were T-cell depleted using
the CliniMacs CD34 columns (Miltenyi). Cell doses of the grafts
were: 4.9 -42.7 x 106 CD34 cells/Kg and 2.24- 49.90 x 103 CD3
cells/Kg.
